LENZ Therapeutics (NASDAQ:LENZ) vs. PharmaCyte Biotech (OTCMKTS:PMCBD) Head-To-Head Comparison

LENZ Therapeutics (NASDAQ:LENZ) and PharmaCyte Biotech (OTCMKTS:PMCBD) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, analyst recommendations, risk, dividends and valuation.

Insider & Institutional Ownership

54.3% of LENZ Therapeutics shares are owned by institutional investors. Comparatively, 0.0% of PharmaCyte Biotech shares are owned by institutional investors. 38.4% of LENZ Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares LENZ Therapeutics and PharmaCyte Biotech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
LENZ Therapeutics	N/A	-39.55%	-33.40%
PharmaCyte Biotech	N/A	-49.09%	-43.39%

Analyst Ratings

This is a summary of current ratings and target prices for LENZ Therapeutics and PharmaCyte Biotech, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENZ Therapeutics	0	0	5	0	3.00
PharmaCyte Biotech	0	0	0	0	N/A

LENZ Therapeutics presently has a consensus target price of $31.33, suggesting a potential upside of 103.60%. Given LENZ Therapeutics’ higher possible upside, equities research analysts plainly believe LENZ Therapeutics is more favorable than PharmaCyte Biotech.

Valuation & Earnings

This table compares LENZ Therapeutics and PharmaCyte Biotech’s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LENZ Therapeutics	N/A	N/A	-$124.65 million	N/A	N/A
PharmaCyte Biotech	N/A	N/A	-$3.83 million	N/A	N/A

Volatility & Risk

LENZ Therapeutics has a beta of 0.33, meaning that its stock price is 67% less volatile than the S&P 500. Comparatively, PharmaCyte Biotech has a beta of 0.27, meaning that its stock price is 73% less volatile than the S&P 500.

Summary

LENZ Therapeutics beats PharmaCyte Biotech on 7 of the 8 factors compared between the two stocks.

About LENZ Therapeutics

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

About PharmaCyte Biotech

PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes. The company was founded on October 28, 1996 and is headquartered in Laguna Hills, CA.